Alcedis
Alcedis GmbH is a German digital-first Contract Research Organization serving global pharmaceutical, biotechnology, medical device, and academic clients with full-service clinical trial execution, a proprietary EDC/eCRF and mobile platform, AI-assisted data management, and Real-World Evidence capabilities enabled by Samsung and CGM MARE partnerships.
- Company typePrivate
- Founded1992
- HeadquartersGießen, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Alcedis does
Alcedis GmbH is a German digital-first Contract Research Organization (CRO) founded in 1992 by Michael Lorsbach and headquartered in Gießen, Germany. The company delivers full-service clinical trial execution spanning Phase I through Phase IV, including clinical project management, data management, regulatory affairs, monitoring, biostatistics, medical writing, and pharmacovigilance, across therapeutic areas such as cardiology, oncology, respiratory, diabetes, neurology, and ophthalmology. Its named customer base includes global pharmaceutical companies (AstraZeneca, Bayer, Lilly, Boehringer Ingelheim, Janssen Cilag, MSD), biotechnology firms (Curevac, lophius, Scandion), medical device manufacturers, and academic medical centers, with case-study scale reaching 10,000 participants (HEARTBEAT), 5,191 (HANSE), and 800,000+ datasets (InspeCKD).
The company's technical differentiator is the proprietary Alcedis Platforms suite, an integrated digital clinical research stack combining electronic data capture (EDC/eCRF), patient-facing mobile applications for ePRO and engagement, specialized plugins (Tech-Ons) for laboratory templates, MedDRA/WHO/ICD-10 coding, RECIST tumor assessment, randomization, and visual documentation, all connected through a REST-API integration layer. AI capabilities are delivered through Meteor (NLP for unstructured clinical text in data management and pharmacovigilance) and Alcedis Labs (predictive analytics, computer vision for CT imaging, and biomarker algorithm development). Distribution is amplified by two flagship partnerships: Samsung Electronics for wearable biosensors and Galaxy Watch-based digital endpoints, and CGM MARE / CompuGroup Medical providing exclusive access to 21 million+ longitudinal patient records across 6,500+ office-based physicians in Germany, Austria, France, and the US for Real-World Evidence generation.
Revenue is generated through a hybrid model combining professional services fees for CRO engagements and recurring technology licensing for Alcedis Platforms. The go-to-market is enterprise field sales with direct expert consultation; no public pricing is disclosed. Alcedis operates as a Huma Company, integrating Huma's healthcare AI cloud platform for regulatory-cleared SaMD-grade biomarker deployment, with the managing board consisting of Hanno Härtlein, Alexander Heinz, and Dr. Bernhard Remes.
Alcedis firmographics
Firmographics- Name
- Alcedis
- Legal name
- Alcedis GmbH
- Website
- https://alcedis.de
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Alcedis GmbH is a German digital-first Contract Research Organization serving global pharmaceutical, biotechnology, medical device, and academic clients with full-service clinical trial execution, a proprietary EDC/eCRF and mobile platform, AI-assisted data management, and Real-World Evidence capabilities enabled by Samsung and CGM MARE partnerships.
- Ownership category
- akta.pro rank
Alcedis industry classification
Industry- Product category
- Clinical Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Software Publishers (513210)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Electronic Data Capture (EDC) Platforms (HLACAOAA), eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)
Keywords
Where Alcedis is headquartered
LocationHeadquarters
- HQ city
- Gießen
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Alcedis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CRO Services: Full-service Contract Research Organization offering comprehensive clinical trial services including clinical project management, data management, regulatory affairs, monitoring, biostatistics, medical writing, and pharmacovigilance. Revenue is generated through service fees for study execution across Phase I to Phase IV clinical trials, as well as observational studies and non-interventional studies.
- Technology Platforms: Alcedis Platforms software licensing and technology services including EDC/eCRF systems, mobile applications, and integration services. The platform serves as both internal infrastructure and external product offering.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Alcedis product offering
Product offeringCore offering
Alcedis is a digital clinical research organization (CRO) that delivers end-to-end clinical trial services across Phase I-IV, observational studies, and Real-World Evidence programs. Its offering combines full-service CRO capabilities (clinical project management, data management, regulatory affairs, monitoring, biostatistics, medical writing, pharmacovigilance) with proprietary Alcedis Platforms technology, including EDC/eCRF, mobile apps, AI tools (Meteor), and integrations with wearables and EHR systems.
Product overview
Alcedis is a digital-first clinical research organization (CRO) offering a unified platform architecture called Alcedis Platforms that combines proprietary technology products with integrated partner services. The core technology stack includes EDC/eCRF for electronic data capture, Mobile Apps for patient-reported outcomes and engagement, and Tech-Ons (specialized eCRF plugins). AI capabilities are delivered through Meteor (text review) and Alcedis Labs. The platform connects to third-party services via REST-API, including Samsung wearable biosensors and CGM MARE EHR systems. Alcedis also provides full-service CRO offerings spanning clinical operations, regulatory affairs, biometrics, and pharmacovigilance across multiple therapeutic areas.
Differentiator
Problem solved
Functional benefit
Brands
- Alcedis Platforms: Proprietary technology platform combining EDC systems, IT infrastructure, mobile apps, plugins, and integrations for clinical research.
- Alcedis Labs
- Meteor
Products and services
- CRO Services End-to-end full-service clinical research organization (CRO) offering Clinical Project Management, Data Management, Regulatory Affairs, Monitoring, Biostatistics, Medical Writing, and Pharmacovigilance services across Phase I-IV clinical trials, observational studies, and non-interventional studies, targeting pharmaceutical, biotech, and academic clients.
- Alcedis Platforms Central technology platform for multi-channel data integration within clinical trials, combining proprietary EDC systems, IT infrastructure, mobile applications, and REST-API integrations with partner technologies into a unified clinical research ecosystem.
- EDC / eCRF Electronic data capture and electronic case report form system enabling structured, real-time clinical data collection with automatic plausibility checks and regulatory compliance for clinical trial sponsors.
- Mobile Apps Mobile applications including ePRO (electronic Patient Reported Outcomes), eDiary, consent management, and patient engagement apps enabling remote data collection and telemedicine features for decentralized clinical trials.
- Meteor AI-supported tool for reviewing free texts in data management and pharmacovigilance workflows, leveraging AI to analyze and process unstructured clinical documentation.
- Alcedis Labs AI-focused research and development initiatives including advanced analytics, machine learning algorithms, and AI-driven biomarker algorithm development for clinical applications.
Quantifiable outcome
- Sensor configuration and device set-up in under 6 weeks
- +6 more outcomes
Companies that use Alcedis
Customer profileNamed customers20 records
Segments4 records
Ideal customer profiles3 records
Alcedis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability7 records
Feature7 records
Alcedis partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Samsung ElectronicsflagshipStrategic partnership to advance biomarker development and clinical endpoints from early-phase research to Real-World Evidence. Samsung provides advanced wearable technology including Galaxy Watch devices with bioelectrical impedance analysis, electrodermal activity sensors, and SaMD features for sleep apnea and atrial fibrillation detection. Alcedis leads study execution, participant engagement, and evidence generation. The partnership creates an end-to-end evidence-generation ecosystem for wearable-derived data across the entire drug development lifecycle. Configured sensor selection and raw biosensor signals are accessible through Samsung's research platform.
- CGM MARE (CompuGroup Medical)flagshipPartnership combining 30+ years of clinical research expertise with access to CGM MARE's medical practice-software network spanning Germany, Austria, France, and the US. Provides exclusive access to longitudinal EHR data from 6,500+ office-based physicians and 21 million patient records. Enables faster cohort identification, cleaner data, and Real-World Evidence generation. The joint infrastructure powers automated transfer of structured EHR data into Alcedis Platforms eCRF.
- HumacoreAlcedis is a Huma company. Huma provides the cloud platform infrastructure for biomarker algorithm co-development and regulatory-cleared SaMD-grade deployment. The partnership enables digital endpoint innovation and biomarker development combining Samsung's hardware capabilities with Alcedis's clinical trial infrastructure under Huma's healthcare AI platform.
Scale indicators6 records
Recent moves3 records
Expansion highlights6 records
Alcedis competitors and assessment
Company assessmentDirect peers
- Castor EDC: Amsterdam-based digital-first EDC platform serving clinical research with comparable scale and tech-enabled approach. Competes directly with Alcedis Platforms for EDC selection in DCT and academic trials.
- Clario: Provides eCOA, EDC, imaging, and cardiac safety solutions for clinical trials. Closely overlaps with Alcedis's ePRO, EDC, and AI imaging capabilities, particularly for decentralized and hybrid trial designs.
- Ergomed: European-headquartered CRO with similar mid-market positioning and specialty pharma/biotech focus. Comparable geographic profile and customer mix to Alcedis's European enterprise pharma base.
Broad incumbents
- Medidata Solutions: Dassault Systèmes-owned clinical cloud platform offering Rave EDC, eCOA, CTMS, and analytics. Much larger scale but core overlap with Alcedis Platforms on EDC and eCOA functionality.
- Veeva Systems: Provides Vault CTMS, Vault EDC, and eTMF as part of a broader life sciences platform. Operates as a broad incumbent in clinical operations technology with overlapping EDC and clinical data management capabilities.
- IQVIA: World's largest CRO with full Phase I-IV services plus tech-enabled DCT offerings through Patient Centric Solutions. Sets the competitive ceiling on enterprise pharma CRO contracts.
- ICON plc: Global CRO with comprehensive Phase I-IV services and growing technology and decentralized trial capabilities. Direct competitor for European enterprise pharma CRO engagements.
- Parexel: Large global CRO offering full-service clinical development, including biotech-focused and DCT capabilities. Competes for the same biotech and pharma customer base Alcedis serves.
Emerging players
- Science 37: DCT-native CRO specializing in fully decentralized clinical trials. Competes for the same biotech and specialty pharma segment that values Alcedis's wearable integration and mobile patient data capabilities.
- ObvioHealth: DCT-focused CRO with mobile and wearable-native trial design. Overlaps with Alcedis's decentralized trial, mobile app, and wearable integration approach at the emerging end of the market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Alcedis social profiles
Digital presenceAlcedis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alcedis leadership team
Management profileNumber of profiles
Profiles9 records
Alcedis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alcedis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alcedis
What does Alcedis do?
Alcedis is a digital clinical research organization (CRO) that delivers end-to-end clinical trial services across Phase I-IV, observational studies, and Real-World Evidence programs. Its offering combines full-service CRO capabilities (clinical project management, data management, regulatory affairs, monitoring, biostatistics, medical writing, pharmacovigilance) with proprietary Alcedis Platforms technology, including EDC/eCRF, mobile apps, AI tools (Meteor), and integrations with wearables and EHR systems.
Is Alcedis a public or private company?
Alcedis is a private company. It is classified as corporate owned and is currently operating.
When was Alcedis founded?
Alcedis was founded in 1992. It employs 51 to 100 people.
Where is Alcedis based?
Alcedis is headquartered in Gießen, Germany, in the Europe region.
How does Alcedis make money?
Two revenue lines are on record. CRO Services are the primary driver. The others are technology Platforms.
Who are Alcedis's main competitors?
Direct peers on record are Castor EDC, Clario and Ergomed. Broad incumbents are Medidata Solutions, Veeva Systems, IQVIA, ICON plc and Parexel. Emerging players are Science 37 and ObvioHealth.
Does Alcedis have an API?
No public API is recorded for Alcedis.
What industry is Alcedis in?
Alcedis's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLACAOAA, Electronic Data Capture (EDC) Platforms. Its NAICS code is 5417 and its SIC code is 8731.